| Identification | Back Directory | [Name]
Benzamide, N-[4-(1-methylethoxy)phenyl]-4-(2H-tetrazol-5-yl)- | [CAS]
1026652-90-3 | [Synonyms]
Xanthine oxidoreductase-IN-5
Benzamide, N-[4-(1-methylethoxy)phenyl]-4-(2H-tetrazol-5-yl)- | [Molecular Formula]
C17H17N5O2 | [MOL File]
1026652-90-3.mol | [Molecular Weight]
323.35 |
| Hazard Information | Back Directory | [Uses]
Xanthine oxidoreductase-IN-5 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC50 of 55 nM. Xanthine oxidoreductase-IN-5 can be used for the research of acute hyperuricemia[1]. | [in vivo]
Xanthine oxidoreductase-IN-5 (compound IIIe) (5 mg/kg; p.o.) shows a uric acid-lowering effect from 5 h after administration in mice with acute hyperuricemia[1]. | Animal Model: | ICR mice (18-22 g) were induced acute hyperuricemia by injection of potassium oxonate and hypoxanthine[1] | | Dosage: | 5 mg/kg | | Administration: | Suspended in 0.5% CMC-Na solution for intragastric administration | | Result: | Showed a uric acid-lowering effect from 5 h after administration.
|
| [References]
[1] Peng W, et, al. Design, synthesis, and evaluation of tricyclic compounds containing phenyl-tetrazole as XOR inhibitors. Eur J Med Chem. 2022 Nov 28;246:114947. DOI:10.1016/j.ejmech.2022.114947 |
|
|